Leading Researchers Join Biogen Idec (BIIB) To Advance Drug Discovery For Neurodegenerative Diseases

Leading Researchers Join Biogen Idec (BIIB) To Advance Drug Discovery For Neurodegenerative Diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that two leading neuroscientists have joined the company to advance its research in neurodegenerative diseases. Christopher Henderson, Ph.D., joins as vice president, Neurology. Richard Ransohoff, M.D., joins as senior research fellow, Neuroimmunology. The addition of these top researchers bolsters Biogen Idec's discovery engine. 

Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.